Dermtech Stock News

Equities research analysts forecast that DermTech, Inc. (NASDAQ:DMTK) will report $3.50 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for DermTechs earnings. The highest sales estimate is $3.80 million and the lowest is $2.90 million. DermTech posted sales of $2.12 million during the same quarter []

We review 5 top stock ideas that have been created by the Fed's tomfoolery (3 are pure-growth stocks and 2 are dividend-growth stocks). We also discuss a big reason why cryptocurrency popularity conti

DermTech, Inc. (NASDAQ:DMTK) COO Claudia Ibarra sold 3,450 shares of the businesss stock in a transaction that occurred on Wednesday, December 8th. The shares were sold at an average price of $18.46, for a total transaction of $63,687.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this []

Skin-cancer detection could lead to big returns for this stock.

Skin-cancer detection could lead to big returns for this stock.

Goldman Sachs Group Inc. lifted its stake in shares of DermTech, Inc. (NASDAQ:DMTK) by 37.6% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 22,962 shares of the companys stock after buying an additional 6,275 shares during the quarter. Goldman Sachs Group []

Morgan Stanley raised its holdings in shares of DermTech, Inc. (NASDAQ:DMTK) by 33.6% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 181,669 shares of the companys stock after acquiring an additional 45,641 shares during the quarter. Morgan Stanley owned about 0.61% of DermTech []

Metropolitan Life Insurance Co NY raised its holdings in DermTech, Inc. (NASDAQ:DMTK) by 225,600.0% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 6,771 shares of the companys stock after acquiring an additional 6,768 shares during the quarter. Metropolitan Life Insurance Co NYs holdings in []

Charles Schwab Investment Management Inc. boosted its position in shares of DermTech, Inc. (NASDAQ:DMTK) by 92.9% during the 2nd quarter, HoldingsChannel.com reports. The fund owned 59,073 shares of the companys stock after buying an additional 28,443 shares during the quarter. Charles Schwab Investment Management Inc.s holdings in DermTech were worth $2,456,000 as of its most []

During the last session, DermTech Inc. (NASDAQ:DMTK)s traded shares were 0.35 million, with the beta value of the company hitting 0.75. At the end of the trading day, the stocks price was $20.43, reflecting an intraday loss of -0.05% or -$0.01. The 52-week high for the DMTK share is $84.49, that puts it down -313.56 DermTech Inc. (NASDAQ: DMTK) Is Down -28.69% In A Month. Could There Be Any Hope That It Will Rise Soon? Read More »

Wedbush Securities Inc. grew its position in DermTech, Inc. (NASDAQ:DMTK) by 47.6% in the third quarter, according to its most recent filing with the SEC. The fund owned 15,489 shares of the companys stock after acquiring an additional 4,994 shares during the period. Wedbush Securities Inc.s holdings in DermTech were worth $497,000 as of its []

Nothing major changed for the skin genomics company in Q3.

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (DermTech), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its session presentation, focused on non-invasive precision dermatology approaches, at the fifth annual Dermatology Drug Development Summit for Inflammatory Skin Diseases. Held in Boston this year, the Dermatology Drug Development Summit is a prestigious forum committed to overcoming significant R&D hurdles and sha

Both companies offer disruptive new solutions in their niches of the healthcare space.